Search - tctmd.com

Displaying 621 - 640 of 1616

Sort: Relevancy | Date

News Conference News ESC 2019

POPULAR AGE Supports Clopidogrel Over Ticagrelor in Elderly ACS Patients

Michael O'Riordan

August 31, 2019

News Conference News ESC 2019

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Yael L. Maxwell

August 31, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for August 2019

Shelley Wood

August 30, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Todd Neale

August 23, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

Caitlin E. Cox

August 21, 2019

News Daily News

TAVR Bleeds Stand Apart From PCI-Related Events

Caitlin E. Cox

August 06, 2019

News Daily News

Best Strategy Questioned for NSTE ACS Patients With Prior CABG

Shelley Wood

August 05, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for July 2019

Shelley Wood

July 31, 2019

News Daily News

Baseline Ischemia Not Linked to 10-Year Events in Stable CAD: MASS II Analysis

Shelley Wood

July 23, 2019

News Industry News

FDA approves Bayer's Gadavist® (gadobutrol) injection as the first and only contrast agent for use in cardiac MR in adult patients with known or suspected coronary artery disease

July 15, 2019

Presentation SCCT 2019

Patients with high risk of CAD but no known CAD should go to CTA first vs. Functional first

Presenter: Marcelo F. Di Carli

July 11, 2019

News Daily News

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Michael O'Riordan

July 03, 2019

News Daily News

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

Todd Neale

June 26, 2019

News Conference News TVT 2019

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

Michael O'Riordan

June 13, 2019

News Daily News

Platelet Function and Genetic Testing to Guide P2Y12 Inhibitor Meds in PCI: Updated Consensus

Caitlin E. Cox

June 13, 2019

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

Advertisement

POPULAR AGE Supports Clopidogrel Over Ticagrelor in Elderly ACS Patients

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

TCTMD’s Top 10 Most Popular Stories for August 2019

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

TAVR Bleeds Stand Apart From PCI-Related Events

Best Strategy Questioned for NSTE ACS Patients With Prior CABG

TCTMD’s Top 10 Most Popular Stories for July 2019

Baseline Ischemia Not Linked to 10-Year Events in Stable CAD: MASS II Analysis

FDA approves Bayer's Gadavist® (gadobutrol) injection as the first and only contrast agent for use in cardiac MR in adult patients with known or suspected coronary artery disease

Patients with high risk of CAD but no known CAD should go to CTA first vs. Functional first

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

Platelet Function and Genetic Testing to Guide P2Y12 Inhibitor Meds in PCI: Updated Consensus

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content